BridgeMD
New treatment option for Multiple Sclerosis, Relapsing-Remitting
Official title Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis
ClinicalTrials.gov ID: NCT06569550
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS) of the left premotor cortex can lessen fatigue in patients with Multiple Sclerosis, and if this is a feasible intervention. It will also give further information on fatigue in Multiple Sclerosis.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- A confirmed diagnosis of relapse-remitting or secondary progressive multiple sclerosis, according to most recent McDonald's criteria (Thompson et...
- Must have fatigue as a complaint, and an FSMC score corresponding to at least moderate fatigue (\>53)
- Stable MS medication for at least 3 months
You likely can't join if
- Pregnancy, any subject with the potential to become pregnant must ensure against this (e.g. by taking oral contraceptives, or other high how well it...
- MS Relapse or steroid treatment within 3 months prior to inclusion
- Current treatment targeted towards fatigue, or previous if discontinued within 3 months prior to inclusion
- History of neurologic disease or other significant medical conditions, aside from MS
- EDSS \> 6.5
- Major psychiatric disorder, including current clinical depression.
See the full eligibility criteria
- A confirmed diagnosis of relapse-remitting or secondary progressive multiple sclerosis, according to most recent McDonald's criteria (Thompson et al., 2018). This diagnosis must not be more recent than 3 months
- Must have fatigue as a complaint, and an FSMC score corresponding to at least moderate fatigue (\>53)
- Stable MS medication for at least 3 months
- Pregnancy, any subject with the potential to become pregnant must ensure against this (e.g. by taking oral contraceptives, or other high how well it works method)
- MS Relapse or steroid treatment within 3 months prior to inclusion
- Current treatment targeted towards fatigue, or previous if discontinued within 3 months prior to inclusion
- History of neurologic disease or other significant medical conditions, aside from MS
- EDSS \> 6.5
- Major psychiatric disorder, including current clinical depression.
- Intake of medication that primarily acts on CNS or neurotransmission, except SSRI or SNRI
- Pacemaker or other implanted electronic devices
- Any intracranial metal
- Any metallic implant incompatible with MR scanning
- Claustrophobia
- Either patient or their close relatives suffering from epilepsy
- Current Drug or alcohol abuse
The study team makes the final eligibility decision.
Where it's taking place
- Hvidovre, Capital Region, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hvidovre, Capital Region, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.